NYSE:BMY - New York Stock Exchange, Inc. - US1101221083 - Common Stock - Currency: USD
46.92
-0.71 (-1.49%)
The current stock price of BMY is 46.92 USD. In the past month the price decreased by -2.15%. In the past year, price increased by 18.31%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 56.73 | 739.87B | ||
JNJ | JOHNSON & JOHNSON | 15.52 | 375.37B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 18.69 | 307.35B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.67 | 240.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 15.78 | 215.32B | ||
MRK | MERCK & CO. INC. | 10.39 | 203.22B | ||
PFE | PFIZER INC | 7.91 | 144.29B | ||
SNY | SANOFI-ADR | 10.55 | 117.55B | ||
GSK | GSK PLC-SPON ADR | 8.48 | 77.37B | ||
ZTS | ZOETIS INC | 26.44 | 70.87B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 63.92 | 47.92B | ||
HLN | HALEON PLC-ADR | 20.5 | 46.12B |
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY 10016 US
CEO: Giovanni Caforio
Employees: 34100
Phone: 16092524621
The current stock price of BMY is 46.92 USD. The price decreased by -1.49% in the last trading session.
The exchange symbol of BRISTOL-MYERS SQUIBB CO is BMY and it is listed on the New York Stock Exchange, Inc. exchange.
BMY stock is listed on the New York Stock Exchange, Inc. exchange.
32 analysts have analysed BMY and the average price target is 55.96 USD. This implies a price increase of 19.28% is expected in the next year compared to the current price of 46.92. Check the BRISTOL-MYERS SQUIBB CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BRISTOL-MYERS SQUIBB CO (BMY) has a market capitalization of 95.49B USD. This makes BMY a Large Cap stock.
BRISTOL-MYERS SQUIBB CO (BMY) currently has 34100 employees.
BRISTOL-MYERS SQUIBB CO (BMY) has a resistance level at 47.3. Check the full technical report for a detailed analysis of BMY support and resistance levels.
The Revenue of BRISTOL-MYERS SQUIBB CO (BMY) is expected to decline by -3.38% in the next year. Check the estimates tab for more information on the BMY EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BRISTOL-MYERS SQUIBB CO (BMY) has a dividend yield of 5.32%. The yearly dividend amount is currently 2.42. Check the full fundamental report for a detailed analysis of BMY dividend history, reliability and sustainability.
BRISTOL-MYERS SQUIBB CO (BMY) will report earnings on 2025-07-31, before the market open.
The PE ratio for BRISTOL-MYERS SQUIBB CO (BMY) is 6.39. This is based on the reported non-GAAP earnings per share of 7.34 and the current share price of 46.92 USD. Check the full fundamental report for a full analysis of the valuation metrics for BMY.
The outstanding short interest for BRISTOL-MYERS SQUIBB CO (BMY) is 1.65% of its float. Check the ownership tab for more information on the BMY short interest.
ChartMill assigns a fundamental rating of 6 / 10 to BMY. BMY has an excellent profitability rating, but there are some minor concerns on its financial health.
Over the last trailing twelve months BMY reported a non-GAAP Earnings per Share(EPS) of 7.34. The EPS increased by 599.05% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 11.38% | ||
ROA | 5.86% | ||
ROE | 31.16% | ||
Debt/Equity | 2.67 |
ChartMill assigns a Buy % Consensus number of 68% to BMY. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 499.13% and a revenue growth -3.38% for BMY